GDTC

CytoMed Therapeutics Limited (GDTC) is an innovative pre-clinical biopharmaceutical company based in Singapore, dedicated to advancing cell-based immunotherapies for the treatment of diverse cancer types. By leveraging state-of-the-art technology and proprietary research, the firm develops therapeutic candidates that address critical unmet needs in oncology. With a promising pipeline and a strong commitment to scientific excellence, CytoMed positions itself as a compelling opportunity for institutional investors seeking exposure to the rapidly evolving cancer immunotherapy market.